ScholarIQanswers from OpenAlex
Centre Hospitalier Universitaire de Besançon
InstitutionResearch output, impact & collaborations
Centre Hospitalier Universitaire de Besançon is a institution indexed in ScholarIQ from OpenAlex.
What is known about Centre Hospitalier Universitaire de Besançon?
ScholarIQrecord summary
Centre Hospitalier Universitaire de Besançon is a research organisation in Besançon, FR. OpenAlex records 15,556 works and 773,170 citations for it. 3,385 researchers list it as their most recent affiliation.
How many works does Centre Hospitalier Universitaire de Besançon have?
ScholarIQindexed works
Centre Hospitalier Universitaire de Besançon has 15,556 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Centre Hospitalier Universitaire de Besançon have?
ScholarIQcitation count
Centre Hospitalier Universitaire de Besançon has 773,170 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Centre Hospitalier Universitaire de Besançon?
ScholarIQresearcher count
Centre Hospitalier Universitaire de Besançon has 3,385 researchers in the ScholarIQ index.
What is the average h-index at Centre Hospitalier Universitaire de Besançon?
ScholarIQavg h-index
Centre Hospitalier Universitaire de Besançon has an average h-index of 44 in OpenAlex.
What is the ROR of Centre Hospitalier Universitaire de Besançon?
ScholarIQror
The ROR for Centre Hospitalier Universitaire de Besançon is on the source record.
What is the OpenAlex record for Centre Hospitalier Universitaire de Besançon?
ScholarIQopenalex
The OpenAlex for Centre Hospitalier Universitaire de Besançon is on the source record.
What is the Wikidata of Centre Hospitalier Universitaire de Besançon?
ScholarIQwikidata
The Wikidata for Centre Hospitalier Universitaire de Besançon is on the source record.
Who are the most-cited researchers behind Centre Hospitalier Universitaire de Besançon?
ScholarIQtop researchers by citations
What are the most-cited papers on Centre Hospitalier Universitaire de Besançon?
ScholarIQmost cited works
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Eric Assénat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim, Kun‐Ming Rau, Kenta Motomura, Izumi Ohno, Philippe Merle, Bruno Daniele, Dong Bok Shin, Guido Gerken, Christophe Borg, Jean‐Baptiste Hiriart, Takuji Okusaka, Manabu Morimoto, Yanzhi Hsu, Paolo Abada, Masatoshi Kudo
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
Joseph M. Braun, Rosaline van den Berg, Xenofon Baraliakos, Heinrich Boehm, R Burgos-Vargas, Eduardo Collantes‐Estévez, Hanne Dagfinrud, Ben A. C. Dijkmans, Maxime Dougados, Paul Emery, Pál Géher, M. Hammoudeh, RD Inman, Merryn Jongkees, MA Khan, Uta Kiltz, Tore K Kvien, Marjatta Leirisalo‐Repo, Walter P. Maksymowych, Ignazio Olivieri, Karel Pavelká, J. Sieper, Ewa Stanisławska‐Biernat, Daniel Wendling, Salih Özgöçmen, C van Drogen, Barend J. van Royen, D. van der Heijde
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Sun Young Rha, Sun Young Rha, Do-Youn Oh, Patricio Yañez, Yuxian Bai, Min-Hee Ryu, Jeeyun Lee, Fernando Rivera, Gustavo Vasconcelos Alves, Marcelo Garrido, Kai-Keen Shiu, Manuel González Fernández, Jin Li, Maeve A Lowery, Timuçin Çil, Felipe Melo Cruz, Shukui Qin, Suxia Luo, Hongming Pan, Zev A Wainberg, Lina Yin, Sonal Bordia, Pooja Bhagia, Lucjan S Wyrwicz, Guillermo Méndez, Juan Manuel O’Connor, Alvaro Yanzi Castilla, Juan Cundom, Diego Kaen, Rachel Wong, Weng Ng, Morteza Aghmesheh, Mauricio Peressoni, Carlos Eduardo Mattos da Cunha Andrade, Fábio Franke, Gustavo R. Alves, Felipe Jose Cruz, Karina Vianna, Maria Marcela Monteiro, Michael J. Raphael, Scott Berry, Raymond Woo-Jun Jang, Ann Tan, Jamil Asselah, Patricio Yañez Weber, Mauricio Mahave, César Sánchez, Pamela Salman, Yuxian Bai, Jin Li, Xiaochun Zhang, Tianshu Liu, Xiaoyan Lin, Shukui Qin, Jianwei Yang, Suxia Luo, Wěi Li, Jieer Ying, Xi Chen, Shan Zeng, Yanli Qu, Lin Yang, Lin Zhao, Ping Chen, Hongming Pan, Enxiao Li, Feng Ye, Jianwei Lu, Xinjun Liang, Qun Zhao, Xianli Yin, Junhe Li, Ling Yang, Guoqing Lv, Shouguo Li, Álvaro Guerrero, Juan Rubiano, Manuel Gonzalez Fernandez, Ray Manneh Kopp, Adrián Guzmán Ramírez, Luis Corrales, Ileana Gonzalez Herrera, Bohuslav Melichar, Tomáš Büchler, Tomáš Svoboda, Radka Obermannová, David Vrána, Jakub Cvek, Per Pfeiffer, Lene Bæksgaard, Mette Yilmaz, Valérie Boige, Daniel López‐Trabada, Christophe Borg, Diane Pannier, Sandrine Hiret, Frédéric Di Fiore, Jean‐Philippe Metges, Dirk Arnold, Uwe M. Martens
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
Shukui Qin, Minshan Chen, Ann‐Lii Cheng, Ahmed O. Kaseb, Masatoshi Kudo, Han Chu Lee, Adam C. Yopp, Jian Zhou, Lu Wang, Xiaoyu Wen, Jeong Heo, Won Young Tak, Shinichiro Nakamura, Kazushi Numata, Thomas Uguen, David Hsiehchen, Edward Cha, Stephen P. Hack, Qinshu Lian, Ning Ma, Jessica Spahn, Yulei Wang, Lyndia C. Wu, Pierce K. H. Chow, Alexander Thompson, Mark Danta, Pirooz Poursoltan, Andrew Ddembe Kiberu, Renuka Chittajallu, Siddarth Sood, Rudolf Stauber, Matthias Pinter, Markus Peck‐Radosavljevic, Jochen Decaestecker, Pieter‐Jan Cuyle, Gontran Verset, Hans Van Vlierberghe, Sérgio de Azevedo, Livia Andrade, Ademar Cunha Júnior, Luiza Dib Batista Bugiato Faria, Cheng Tzu Yen, Leandro M. Colli, Jamil Asselah, Petr Kavan, Vladimir Marquez, Mayur Brahmania, Qiang Li, Bao-Cai Xing, Yabing Guo, Zhendong Chen, Haitao Zhao, Tao Peng, Liming Wang, Lu Wang, Hongming Liu, Feixiang Wu, Lun–Xiu Qin, Qichang Zheng, Jieer Ying, Haitao Li, Tianfu Wen, Shukui Qin, Xiaoyu Wen, Yunpeng Liu, Minshan Chen, Boqing Wang, Yuxian Bai, Yifu He, Hong Zhao, Dong Zhou, Chaoliu Dai, Gao‐Jun Teng, Shuzhong Cui, Yi Gao, Xizhi Zhang, Zheng Lu, Tao Yin, Youming Ding, Weidong Jia, Yongxiang Xia, Beicheng Sun, Qiang Xia, Yufeng Yuan, Hui‐Chuan Sun, Xuetao Shi, A. Guzmán, Luis Corrales, Zdeněk Král, Peter Priester, Eugen Kubala, Jean Frédéric Blanc, Marc Bourlière, Jean Marie Péron, Christophe Borg, Jean–Pierre Bronowicki, Nathalie Ganne, Thomas Decaens, Thomas Uguen, Alexandra Heurgué
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Lin Shen, Ken Kato, Sung‐Bae Kim, Jaffer A. Ajani, Kuaile Zhao, Zhiyong He, Xinmin Yu, Yongqian Shu, Qi Luo, Jufeng Wang, Zhendong Chen, Zuoxing Niu, Longzhen Zhang, Tienan Yi, Jong‐Mu Sun, Jianhua Chen, Guohua Yu, Chen‐Yuan Lin, Hiroki Hara, Qing Bi, Taroh Satoh, Roberto Pazo-Cid, Hendrick-Tobias Arkenau, Christophe Borg, Florian Lordick, Liyun Li, Ningning Ding, Aiyang Tao, Jingwen Shi, Eric Van Cutsem, for the RATIONALE-302 Investigators
How much of the research on Centre Hospitalier Universitaire de Besançon is open access?
ScholarIQopen access share
67%OPEN ACCESS